Clinical Research Directory

Inclusion Criteria: * Age 6 to 8 years * Meeting DSM-5 criteria for autism spectrum disorder * ASD severity classified as moderate or severe on the ADOS * Mother with : (i) an autoimmune disease (as listed by the American Autoimmune Related Diseases Association: https://www.aarda.org/diseaselist/) that began during the first and second trimesters of pregnancy, or that was present prior to pregnancy and experienced a relapse (defined as a change in disease activity leading to a change/modification of treatment) during pregnancy; (ii) a maternal infection (viral or bacterial) during pregnancy, defined as a fever greater than 38.5°C for at least 48 hours and documented (medical consultation, biological sample, prescription of antipyretic and/or antibiotic). Infections by a pathogen with a well-documented direct cerebral effect (CMV) will be excluded. * Consent of parental authority and social security affiliation * One of whose parents lives in the HAD pediatric intervention area. Exclusion Criteria: * Recent change in ASD management (behavioral therapy within 6 weeks, introduction of psychotropic molecules within 2 weeks) * Contraindication to IL2 use (hypersensitivity, cancer history, active infection, obesity, transplant history, vaccination with live attenuated vaccine within 4 weeks) * Participation in another therapeutic trial within the last 3 months * BMI \>95th percentile or BMI \<5th percentile * Participants who have already received a genetic diagnosis of ASD of the 'syndromic' type by DNA chip chromosome analysis * Participants with hyperchloremia or hypernatremia * Participant with uncontrolled epilepsy. * Participants who are related to a person involved in the study at the investigating centre, the clinical research organisation (CRO) or the sponsor.